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Mosaicism is increasingly recognized as a cause of developmental disorders with the advent of
next-generation sequencing (NGS). Mosaic mutations of PIK3CA have been associated with the
widest spectrum of phenotypes associated with overgrowth and vascular malformations. We
performed targeted NGS using 2 independent deep-coverage methods that utilize molecular
inversion probes and amplicon sequencing in a cohort of 241 samples from 181 individuals with
brain and/or body overgrowth. We identified PIK3CA mutations in 60 individuals. Several other
individuals (n = 12) were identified separately to have mutations in PIK3CA by clinical targetedpanel testing (n = 6), whole-exome sequencing (n = 5), or Sanger sequencing (n = 1). Based on
the clinical and molecular features, this cohort segregated into three distinct groups: (a) severe
focal overgrowth due to low-level but highly activating (hotspot) mutations, (b) predominantly
brain overgrowth and less severe somatic overgrowth due to less-activating mutations, and (c)
intermediate phenotypes (capillary malformations with overgrowth) with intermediately activating
mutations. Sixteen of 29 PIK3CA mutations were novel. We also identified constitutional PIK3CA
mutations in 10 patients. Our molecular data, combined with review of the literature, show that
PIK3CA-related overgrowth disorders comprise a discontinuous spectrum of disorders that correlate
with the severity and distribution of mutations.

Introduction
Mosaicism refers to a biological phenomenon in which an individual derived from a single fertilized egg
has two or more populations of cells with different genotypes. This process can be the result of spontaneous
mutations occurring at different times during the life course of a multicellular organism, and is a widespread
phenomenon during the normal aging process (1). Here, we will refer to somatic mosaicism as a process
occurring strictly during development (postzygotically), excluding mosaicism confined to germ cells (germline mosaicism) and somatic mosaicism associated with cancer (2). While this phenomenon has been known
for many years, the association of mosaic mutations with human disease began with discovery of mosaic
chromosomal disorders, and patchy (or segmental) manifestations of Mendelian disorders (3, 4). The first
sequencing-based proof of mosaic aberrations came in 1991 with discovery of activating mutations of the
GNAS gene in McCune-Albright syndrome (5, 6). Subsequently, an increasing number of other conditions,
largely congenital or childhood-onset developmental disorders, have been associated with mosaic mutations.
Examples include Proteus syndrome (AKT1), Sturge-Weber syndrome (GNAQ), neurocutaneous melanosis
(NRAS), epidermal nevi and linear nevus sebaceous syndrome (HRAS, KRAS, PIK3CA), Maffuci and Ollier
syndromes (IDH1, IDH2), and encephalocraniocutaneous lipomatosis (FGFR1); disorders first proposed to
be mosaic based on their asymmetric, patchy presentation, and lack of familial recurrence (7, 8). Mosaic
mutations of these genes were primarily identified with the advent of massively parallel or next-generation
sequencing (NGS) methods that facilitate detection of low-frequency variation, especially in affected tissues.
However, there are several limitations in our knowledge of mosaic developmental disorders, particularly which molecular diagnostic methods are best, which tissues should be assayed, and the nature and rela-
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Table 1. Cohort of children with brain and/or body overgrowth screened for PIK3CA mutations
CohortA

Sequencing method
Number of patients
Number of samples
Number of mutation-positive patients (%)
Number of mutation-negative patients (%)
Number of samples in each cohort
Blood samples
Saliva samples
Skin samples
Other samples

MCAP

MEG

Somatic overgrowthC

smMIPs/MIPs
131
174
50 (38.2%)
81 (61.8%)

smMIPs
19
36
5 (26.3%)B
14 (73.7%)

smMIPs
31
31
9 (29.1%)
22 (70.9%)

72
71
15
16

12
19
3
2

6
8
10
7

Abbreviations: MCAP, megalencephaly-capillary malformation syndrome; MEG, megalencephaly; MIPs, molecular inversion probes; smMIPs, singlemolecule molecular inversion probes. Notes: APatients identified by other methods including whole-exome sequencing (n = 5), targeted NGS (n = 6), and
Sanger sequencing (n = 1) are excluded from this table. BThis cohort includes patients with mutations in other genes including 2 AKT3 mutation–positive
patients, 1 MTOR mutation–positive patient, and 1 PTEN mutation–positive patient. These individuals are not reported in this study. CIncluding patients
with features of CLOVES, KTS, CMO, and other forms of overgrowth with vascular malformations.

tionship between phenotypes and genotypes. The low-level mosaicism found in these disorders poses significant challenges to conventional clinical diagnostic approaches. Current molecular methods in standard
clinical laboratories rely on Sanger sequencing for single-gene analysis, and standard-depth NGS methods
including targeted panels or whole-exome sequencing (with many clinical diagnostic labs using 20× to 30×
as the minimum depth of coverage for putatively constitutional or germline disorders) (9). However, these
methods are not sensitive enough to detect low-level mutations, particularly when the level of mosaicism
is very low (<5%–10%) in the tissue from which DNA is isolated (typically peripheral blood lymphocytes).
Of the genes associated with mosaicism in developmental disorders, mutations of PIK3CA have been associated with the widest spectrum of developmental phenotypes to date, with most described as distinct clinical
entities long before the link to PIK3CA was discovered (10). PIK3CA encodes the alpha catalytic subunit of
phosphatidylinositol-4,5-bisphosphate 3-kinase, a central member of the phosphatidylinositol 3-kinase (PI3K)
enzyme family (11). PIK3CA functions as an oncogene, and activating (or gain-of-function) mutations of
PIK3CA are widely seen in human cancers (12, 13). The most common PIK3CA mutations are p.Glu542Lys,
p.Glu545Lys, and p.His1047Arg, which are seen in ~80% of somatic tissues in cancer (and therefore termed
“hotspot” mutations). Based on their degree of activity, several other classes of PIK3CA mutations have been
described including strong, intermediate, and weak (13). Some of these same gain-of-function PIK3CA mutations have been recently reported in a range of pediatric developmental phenotypes. These disorders are
broadly characterized by cutaneous vascular malformations
with segmental overgrowth and involve multiple tissues or
body regions. These conditions have been variably classified
as Klippel-Trenaunay (KTS), congenital lipomatosis with
overgrowth, vascular malformations, epidermal nevi, and
skeletal/scoliosis/spinal abnormalities (CLOVES), megalencephaly-capillary malformation syndrome (MCAP), and
dysplastic megalencephaly (DMEG), but the spectrum and
differences between these disorders have not been defined.

Figure 1. Levels of mosaicism in PIK3CA by sample type. Dot
blot graph showing alternative allele percentages (AAPs) clustered by type of tissue in all mutation-positive individuals (n =
72). Horizontal bars indicate the mean AAP within each sample
type: red = blood (n = 44); blue = saliva (n = 38); orange = skin
fibroblasts (n = 26). Two-tailed t test (P values): blood-saliva: P =
0.035; blood-skin: P = 0.036; saliva-skin, P = 0.65.
insight.jci.org   doi:10.1172/jci.insight.87623
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Here, we report the largest series of patients to date with developmental disorders associated with
PIK3CA mutations, identified using 2 orthogonal deep-targeted NGS methods that utilize molecular inversion probes (MIPs) and amplicon sequencing, to determine the mutational spectrum and quantify mutation
levels in multiple tissues from affected individuals. By combining our data with previous reports, we assess
available clinical molecular diagnostic methods, the most ideal tissue samples to be assayed, and derive genotype-phenotype correlations in this spectrum of disorders. We show that the phenotypes are not simply
related to the level and distribution of PIK3CA mutations, but also to the class of mutation. Specifically, we
show that CLOVES and KTS, as well as most localized lesions, are caused by one of the three most common oncogenic (“hotspot”) mutations or occasionally by strong or intermediate mutations, while MCAP is
caused largely by a different set of less-activating mutations, with a much wider mutational spectrum that
overlaps at only a few strong mutations (13). We also show that mutations are not equally detectable from
apparently unaffected but easily available “surrogate” tissues, with levels of mosaicism on average lower in
peripheral blood lymphocytes than saliva, and lower in saliva than skin fibroblasts.

Results
We screened a cohort of 241 DNA samples from 181 individuals with brain and body overgrowth for
mutations in the PIK3CA gene using two deep NGS methods that utilize MIPs (14, 15) and amplicon
sequencing. This cohort included 131 individuals with features of MCAP, 19 with diffuse brain overgrowth or megalencephaly, and 31 with various forms of somatic overgrowth and vascular malformations including CLOVES, KTS, and capillary malformations with overgrowth (Table 1 and Supplemental
Figure 1; supplemental material available online with this article; doi:10.1172/jci.insight.87623DS1). We
identified mutations of PIK3CA in 60 individuals (33%). Several other patients (n = 12) were identified to
have mutations separately by clinical targeted-panel testing (n = 6), clinical whole-exome sequencing (n =
5), or Sanger sequencing (n = 1), and were included to highlight the clinical and molecular variability of
this spectrum of disorders. This cohort includes one of our previously published MCAP patients, as we
have analyzed several newly acquired tissue samples from this patient in this study (16). The remaining 23
patients with MCAP who were previously published were excluded from this study (16). The mutations
identified, levels of mosaicism, and tissue distribution in this cohort are listed in Tables 2, 3, and 4. The
levels of mosaicism in all tissues of all mutation-positive patients and their parents using all molecular
methods are listed in Supplemental Table 1.

Molecular results
Levels of mosaicism and tissue distribution. We identified 29 mutations of PIK3CA, including 16 novel mutations that have not been previously identified in developmental disorders, to our knowledge. Oncogenic
mutations at all of these amino acid residues were present in the Catalogue of Somatic Mutations in Cancer (COSMIC; http://cancer.sanger.ac.uk/cosmic). None of the mutations were present in public databases including the 1000 Genomes project (http://www.1000genomes.org), the NHLBI Exome Variant
Server (http://evs.gs.washington.edu/EVS), or the Exome Aggregation Consortium (ExAC; http://exac.
broadinstitute.org), with the exception of p.Glu545Lys and p.His1047Arg, which were present at very low
frequencies in ExAC (<0.0001). Alternative allele percentages (the percentage of alternate or mutant reads
to total reads; AAP) ranged from 1% to 59.5% across the entire cohort (Tables 2, 3, and 4 ). We observed
substantial variation in AAPs in multiple samples from the same individual, with levels of mosaicism
in blood (peripheral lymphocytes) ranging from undetectable to 59.5% (mean AAP 16.5%; 43 samples),
saliva (lymphocytes and epithelial cells) from undetectable to 54% (mean AAP 24%; 37 samples), and
skin-derived fibroblasts from 4% to 60% (mean AAP 26.4%; 20 samples). The AAPs grouped by sample
type (blood, saliva, skin fibroblasts) are shown in Figure 1, whereas the AAPs for each sample type in all
mutation-positive individuals are shown in Supplemental Figure 2. For a few individuals, we tested additional sample types including buccal swabs (n = 4 samples), surgically resected tonsils (lymphoid tissue; n =
2), and occipital bone dura mater removed during posterior fossa decompression surgery (n = 1).
Diagnostic testing methods. The average coverage of single-molecule MIPs (smMIPs) was 450.74×, with
an average of 71.27% of coding regions covered by 50 or more capture events, and with 2% being the lower
threshold of mutant allele detection. All amino acid residues in which mutations were previously identified
were well covered by smMIPs in the entire cohort (Supplemental Figure 3). All mutations identified via
smMIPs were confirmed using a second orthogonal method (amplicon sequencing), when sufficient DNA
insight.jci.org   doi:10.1172/jci.insight.87623
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Table 2. PIK3CA mutations and levels of mosaicism — part 1 (n = 22 patients) [PIK3CA: NM_006218.2]
Sample #

Diagnosis

Position

cDNA change

Amino acid
change

Alternative/total alleles (% alt alleles)
Blood

Saliva

PI3K-ABD (AA 16–105) n = 4
p.Arg93GlnA
47%SS
~50%Sanger
p.Arg93GlnA
19%WES
–
p.Pro104LeuA
–
41%MIPs

N
COSMIC

FB

Other
tissues

–
–
49%MIPs

–
–
–

14
14
5

–

–

5

–
–

–
–

13
3

LR14-323C
LR15-238
LR01-060B,C

MCAP
OVG
MCAP

3:178916891
3:178916891
3:178916924

c.278G>A
c.278G>A
c.311C>T

LR13-359

MCAP

3:178916924

c.311C>T

LR15-076C
LR12-365

MEG
MCAP

3: 178921548
3:178921552

c.1030G>A
c.1034A>C

LR11-076
LR13-036C

3:178921566
3:178922324

c.1048G>A
c.1093G>A

p.Asp350AsnA
p.Glu365LysA

12%Amp
52%WES

32%MIPs
–

–
–

10%LB,Amp
–

3
10

LR13-264
LR11-374
LR11-418

MCAP
MEGmacrosomia
MCAP
MCAP
MCAP

3:178922324
3:178922364
3:178922364

c.1093G>A
c.1133G>A
c.1133G>A

p.Glu365LysA
p.Cys378Tyr
p.Cys378Tyr

2%SS
3%MIPs
2%MIPs

–
40%MIPs
–

29%SS
–
–

–
–
–

10
2
2

LR12-131
LR13-328

OVG
MCAP

3:178922364
3:178922364

c.1133G>A
c.1133G>A

p.Cys378Tyr
p.Cys378Tyr

7%MIPs
–

–
–

ds–
–

–
29%BS,

LR12-382
LR14-278C
LR11-200
LR14-358C
LR11-392
LR12-070
LR12-184

MCAP
MCAP
MCAP
MCAP
MCAP
OVG-MD
OVG

3:178922364
3: 178922364
3:178928067
3:178928067
3:178928079
3:178928079
3:178928079

c.1133G>A
c.1133G>A
c.1345C>A
c.1345C>A
c.1357G>A
c.1357G>A
c.1357G>A

p.Pro104LeuA
11%MIPs
42%MIPs
C2 membrane (AA 330–487) n = 18
p.Val344MetA 41.5%WES
–
p.Asn345ThrA
–
39%MIPs

INH

TypeD

De novo Const.
De novo Mosaic
De novo Presumed
Const.
De novo Mosaic
De novo Const.
Mother Presumed
negative Const.
De novo Mosaic
De novo Const.

2
2

NA
De novo
Mother
negative
De novo
De novo

Mosaic
Mosaic
Mosaic
Mosaic
Mosaic

–
–
–
–
–
–
–

2
2
4
4
25
25
25

De novo
De novo
NA
De novo
NA
NA
De novo

Mosaic
Const.
Mosaic
Const.
Mosaic
Mosaic
Mosaic

–
–

25
1

MIPs
B

p.Cys378Tyr
–
p.Cys378Tyr
~50%WES
p.Pro449ThrA
–
p.Pro449ThrA ~50%Sanger
p.Glu453LysA
2%MIPs
p.Glu453LysA
–
p.Glu453LysA 1%Amp, 1%SS

7%
–
–
–
–
0%MIPs
24%MIPs
MIPs

–
–
37%MIPs
–
–
25%MIPs
5%–17%several
skin samples, Amp

LR12-329
LR13048 B,C

OVG-MD
MCAP

3:178928079
c.1357G>A
3:178928078 c.1359_1361delAGA

p.Glu453Lys
p.Glu453del

A

–
45%MIPs

6%
–

MIPs

19%SS
–
–

Mother
negative

Mosaic
Const.

Abbreviations: ABD, adaptor-binding domain; Amp, amplicon sequencing; BS, buccal swab; FB, skin-derived fibroblasts; INH, inheritance; LB,
lymphoblastoid cell line; MEG, megalencephaly; MCAP, megalencephaly-capillary malformation syndrome; MD, macrodactyly; MIPs, molecular inversion
probes; NA, unavailable; OVG, overgrowth; Sanger, Sanger sequencing; SS, Agilent SureSelect; WES, whole-exome sequencing. Protein domains are
adapted from: http://www.uniprot.org/uniprot/P42336#family_and_domains. (13). Notes: ANovel PIK3CA mutations. BExpanded or newly-published
molecular results on previously published patients: LR01-060 (patient 3) (57), LR12-382 (patient 7) (59), and LR13-048 (patient 1) (60). CConstitutional
or apparently constitutional mutations. DMutations were assigned conservatively constitutional when AAP was greater than 35% in blood (lymphocytederived) DNA. Mutations with AAPs less than 35%, particularly in several tissue samples, were assigned as mosaic. Mutations were presumed to be
constitutional when the AAP was greater than 35% in nonblood-derived DNA (particularly saliva). The numbers of COSMIC mutations are based on those
present when the COSMIC database was last accessed in May 2016.

was available. Amplicon sequencing yielded high coverage data for all mutations, with a mean coverage of
1975×. None of these mutations were present in the parents of affected individuals by amplicon sequencing. Overall, AAPs detected by amplicon sequencing were similar to smMIP results, although the latter
were usually slightly higher for the same samples (Supplemental Figure 4). This may be partly due to allelic
bias/preferential amplification of amplicon sequencing when compared to smMIPs.
Clinical testing identified several more patients with PIK3CA mutations. Mutations in 6 individuals were
detected by targeted NGS using the Agilent SureSelect Capture technology. Another 5 were identified using
standard-depth whole-exome sequencing (WES) on blood-derived DNA, and 1 patient was identified to
have a mutation by standard Sanger sequencing. AAPs in these samples ranged from 41%–59.5%, suggesting
constitutional mutations, with the exception of 1 patient (LR15-238) found to have the p.Arg93Gln mutation
insight.jci.org   doi:10.1172/jci.insight.87623
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MCAP
MCAP
MCAP
MCAP
34
MCAP
MCAP
MCAP
MCAP

LR12-037
LR12-109
LR12-345
LR12-418
4%R tonsil, MIPs
LR12-431
LR13-051
LR13-119
LR15-246C

p.Arg115Pro
p.Arg115Pro
p.Arg115Pro
p.Arg115Pro

p.Gly106ValA
6%MIPs
11%MIPs
–
–

34%MIPs

c.2176G>A
c.2176G>A
c.2176G>A
c.2176G>A
Mosaic
c.2176G>A
c.2176G>A
c.2176G>A
c.2176G>A

c.2176G>A
c.2176G>A

c.1635G>T

–
12%MIPs
–
–
5%MIPs
–
–
59.5%WES

p.Glu726Lys
p.Glu726Lys
p.Glu726Lys
p.Glu726Lys

12%MIPs
4%MIPs

3%MIPs

–
0%Amp
–

p.Glu726Lys
p.Glu726Lys
p.Glu726Lys
p.Glu726Lys

p.Glu726Lys
p.Glu726Lys

p.Glu545AspA

p.Glu542Lys
p.Glu545Lys
p.Glu545AspA

–

Other
tissues

–
–
–
–
–
7%MIPs
–
–

11%MIPs
–
7%MIPs
–

–
–

–

–
–
–

9%BS, MIPs
–
–
–

4%L tonsil, MIPs

–
–
–

–
3%LB, MIPs

–

–
–
–

–
50%BS, Sanger
27%MIPs
–
16%MIPs
–
–
–

40%MIPs

FB

20%MIPs
–
14%MIPs
13%MIPs

–
–

25%MIPs

28%MIPs
26%MIPs
44%MIPs

–
–
11%MIPs
25%MIPs

–

Saliva

Alternative/total alleles (% alt alleles)
Blood

Linker region (AA 106–186) n = 5

Amino acid change

Helical domain (AA 517–694) n = 4

c.1624G>A
c.1633G>A
c.1635G>T

c.344G>C
c.344G>C
c.344G>C
c.344G>C

c.317G>T

cDNA change

34
34
34
34

34
34
34

18
34

13

874
1371
13

1
1
1
1

17

N
COSMIC

De novo
De novo
De novo
De novo

NA
Mother
negative
De novo
NA
De novo

NA

De novo
De novo
De novo

NA
De novo
NA
De novo

NA

INH

Mosaic
Mosaic
Mosaic
Const.

Mosaic
Mosaic
Mosaic

Mosaic
Mosaic

Mosaic
Mosaic
Presumed
Const.
Mosaic

Presumed
Const.
Mosaic
Mosaic
Mosaic
Mosaic

TypeD

Abbreviations: Amp, amplicon sequencing; BS, buccal swab; DMEG, dysplastic megalencephaly; FB, skin-derived fibroblasts; INH, inheritance; L, left; LB, lymphoblastoid cell line; LNSS, linear nevus sebaceous
syndrome; MCAP, megalencephaly-capillary malformation syndrome; MEG, megalencephaly; MIPs, molecular inversion probes; NA, unavailable; OVG, overgrowth; R, right; Sanger, Sanger sequencing; SS,
Agilent SureSelect; WES, whole-exome sequencing. Protein domains are adapted from: http://www.uniprot.org/uniprot/P42336#family_and_domains. Notes: Mutations classified as cancer hotspot
mutations (most activating) are highlighted in red (13). ANovel PIK3CA mutations. BExpanded or newly published molecular results on previously published patients: LR12-001 (58) and LR09-142 (61).
C
Constitutional or apparently constitutional mutations. In patient LR12-330, blood-derived DNA was not available for analysis, therefore, the possibility of mosaicism cannot be conclusively excluded.
D
Mutations were assigned conservatively constitutional when the AAP was greater than 35% in blood (lymphocyte-derived) DNA. Mutations with AAPs less than 35%, particularly in several tissue samples,
were assigned as mosaic. Mutations were presumed to be constitutional when the AAP was greater than 35% in nonblood-derived DNA (particularly saliva). The numbers of COSMIC mutations are based on
those present when the COSMIC database was last accessed in May 2016.

3:178938934
3:178938934
3:178938934
3:178938934
NA
3:178938934
3:178938934
3:178938934
3:178938934

3:178938934
3:178938934

3:178936082
3:178936091
3:178936093

MCAP
MCAP

DMEG-LNSS
MEG-DMEG
MCAP

LR12-183
LR13-197
LR12-330C

3:178916957
3:178916957
3:178916957
3:178916957

3:178936093

MCAP
MCAP
MCAP
MCAP

LR04-078
LR11-397
LR12-001B
LR12-080

3:178916930

MCAP

OVG

LR11-082

Position

LR12-019
Linker region (AA 695–796) n = 10
LR09-142B
LR11-072

Diagnosis

Sample #

Table 3. PIK3CA mutations and levels of mosaicism — part 2 (n = 19 patients) [PIK3CA: NM_006218.2]
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Table 4. PIK3CA mutations and levels of mosaicism — part 3 (n = 31 patients) [PIK3CA: NM_006218.2]
Sample #

Diagnosis

Position

cDNA
change

Amino acid change

Alternative/total alleles (% alt alleles)

LR13-045

OVG

3:178947865

c.2740G>A

p.Gly914Arg

–

0%MIPs

LR13-038
LR13-050B
LR12-130
LR12-327

MCAP
MCAP
MCAP
MCAP

3:178947865
3:178947865
3:178947865
3:178947865

c.2740G>A
c.2740G>A
c.2740G>A
c.2740G>A

p.Gly914Arg
p.Gly914Arg
p.Gly914Arg
p.Gly914Arg

3%MIPs
7%MIPs
–
–

LR12-343
LR12-383
LR13-047
LR11-382
LR15-337
LR13-294
LR12-340C

MCAP
MCAP
MCAP
MCAP
MCAP
MCAP
OVG

3:178947865
3:178947865
3:178947865
3:178947865
3:178947865
3:178948044
3:178948100

c.2740G>A
c.2740G>A
c.2740G>A
c.2740G>A
c.2740G>A
c.2816A>G
c.2872C>A

p.Gly914Arg
p.Gly914Arg
p.Gly914Arg
p.Gly914Arg
p.Gly914Arg
p.Asp939GlyA
p.Gln958LysA

LR06-337B
LR13-108

MCAP
MCAP

3:178948136
3:178952006

c.2908G>A
c.3061T>C

LR11-081

MCAP

3:178952018

LR13-169
LR12-462

MCAP
MCAP

LR12-486
LR12-328
LR12-203
LR15-043
LR06-336
LR11-039
LR12-010
LR14-300
LR11-285B

OVG
MCAP
MCAP
MCAP
MCAP
MCAP
MCAP
MCAP
MCAP

N
COSMIC

INH

TypeD

Kinase domain (AA 797–1068) n = 31
–

1

De novo

Mosaic

–
18%MIPs
19%MIPs
6%MIPs

15%MIPs,
5%FB-normal, MIPs
46%MIPs
–
–
–

–
–
–
–

1
1
1
1

Mosaic
Mosaic
Mosaic
Mosaic

30%Amp
–
11%MIPs
2%MIPs
6%SS
32%MIPs
–

54%MIPs
21%MIPs
–
–
–
–
45%MIPs

–
–
–
–
10%SS
–
–

–
–
–
–
–
–
–

1
1
1
1
1
7
0E

De novo
De novo
De novo
Mother
negative
De novo
De novo
NA
NA
NA
De novo
De novo

p.Glu970LysA
p.Tyr1021HisA

19%MIPs
–

–
40%MIPs

–
–

16%LB, MIPs
–

5
4

De novo
De novo

c.3073A>G

p.Thr1025Ala

–

–

39%SS

–

31

NA

3:178952048
3:178952048

c.3103G>A
c.3103G>A

p.Ala1035ThrA
p.Ala1035ThrA

–
–

23%MIPs
–

–
54%MIPs

–
–

3
3

De novo
De novo

3:178952049
3:178952074
3:178952074
3:178952074
3:178952074
3:178952074
3:178952074
3: 178952084
3:178952084

c.3104C>T
c.3129G>T
c.3129G>T
c.3129G>T
c.3129G>T
c.3129G>T
c.3129G>T
c.3139C>T
c.3139C>T

p.Ala1035Val
p.Met1043Ile
p.Met1043Ile
p.Met1043Ile
p.Met1043Ile
p.Met1043Ile
p.Met1043Ile
p.His1047Tyr
p.His1047Tyr

–
–
7%MIPs
–
3%MIPs
3%MIPs
13%MIPs
2%SS
4%MIPs

–
16%MIPs
11%MIPs
–
–
12%MIPs
–
–
25%MIPs

27%MIPs
–
–
30%SS
–
–
29%MIPs
60%SS
–

–
–
–
–
–
–
–
–

4
69
69
69
69
69
69
68
68

De novo
De novo
De novo
NA
NA
De novo
De novo
NA
De novo

Mosaic
Mosaic
Mosaic
Mosaic
Mosaic
Mosaic
Presumed
Const.
Mosaic
Presumed
Const.
Presumed
mosaic
Mosaic
Presumed
mosaic
Mosaic
Mosaic
Mosaic
Mosaic
Mosaic
Mosaic
Mosaic
Mosaic
Mosaic

LR13-172
MCAP-MD 3:178952085
LR13-265B OVG-CLOVES 3:178952085
LR06-340
MCAP
3:178952090
LR12-089
MCAP
3:178952152
LR11-446
MCAP
3:178952152

c.3140A>G
c.3140A>G
c.3145G>A
c.3207A>G
c.3207A>G

p.His1047Arg
p.His1047Arg
p.Gly1049Ser
p.stop1069Trpext*4A
p.stop1069Trpext*4A

1%
0%MIPs
–
22%MIPs
–

1880
1880
24
7
7

NA
NA
NA
De novo
De novo

Mosaic
Mosaic
Mosaic
Mosaic
Mosaic

1%Occipital
bone, MIPs

MIPs

–
–
–
37%MIPs
22%MIPs

–
4%MIPs
–
–
–

–
–
4%LB, MIPs
–
–

Abbreviations: Amp, amplicon sequencing; CLOVES, congenital lipomatous truncal overgrowth, vascular anomalies, epidermal nevi and skeletal/spinal
anomalies; FB; skin-derived fibroblasts; INH, inheritance; LB, lymphoblastoid cell line; MCAP, megalencephaly-capillary malformation syndrome; MD,
macrodactyly; MIPs, molecular inversion probes; NA, unavailable; OVG, overgrowth; SS, Agilent SureSelect. Protein domains are adapted from: http://
www.uniprot.org/uniprot/P42336#family_and_domains. Notes: Mutations classified as cancer hotspot mutations (most activating) are highlighted
in red, intermediate mutations are highlighted in blue (13). ANovel PIK3CA mutations. BExpanded or newly published molecular results on previously
published patients: LR13-050 (patient 2) (60), LR06-337 (patient 14) (31), and LR11-285 (16). CConstitutional or apparently constitutional mutations.
In patients LR13-108 and LR12-462, blood-derived DNA was not available for analysis, therefore, the possibility of mosaicism cannot be conclusively
excluded. DMutations were assigned constitutional when the AAP was greater than 35% in blood (lymphocyte-derived) DNA. Mutations with AAPs less
than 35%, particularly in several tissue samples, were assigned as mosaic. Mutations were presumed to be constitutional when the AAP was greater
than 35% in nonblood-derived DNA (particularly saliva). EOther mutations at this site have been seen in COSMIC. The numbers of COSMIC mutations are
based on those present when the COSMIC database was last accessed in May 2016.

in 30 of 159 reads (19%). AAPs in the 6 patients tested by targeted NGS ranged from 1%–47%. In 2 patients
(LR14-323, LR15-227), AAPs were 47% in blood-derived DNA, again suggesting constitutional mutations.
Overall, we identified 29 PIK3CA mutations in 72 individuals. We also reviewed published data on
PIK3CA mutations in developmental pediatric disorders (all phenotypes except for cancer; Figure 2) (16–
29). When added to our data, we find that all developmental phenotypes combined have been associated
insight.jci.org   doi:10.1172/jci.insight.87623
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Figure 2. Distribution of PIK3CA mutations by functional domain in cancer and developmental (pediatric) disorders. Graph showing the number of published PIK3CA mutations by amino acid location in the Catalogue of Somatic Mutations in Cancer (COSMIC) database of somatic variation in cancer (shown
in green; last accessed May 2016) and in children with developmental disorders comparing the megalencephaly-capillary malformation syndrome (MCAP;
shown in blue) and all other developmental disorders (shown in orange). Mutations shown include those reported in this study as well as published
mutations. Notes: (a) The 2-tailed P value by Fisher’s exact test was less than 0.0001, supporting that the association between MCAP and non-hotspot
mutations and non-MCAP and hotspot associations is extremely statistically significant. (b) “Hotspot” mutations in this analysis are the most activating
mutations in somatic tissues in cancer (p.Glu542Lys, p.Glu545Lys, p.His1047Arg) (13).

with 41 different PIK3CA mutations involving 33 codons and include 27 recurrent mutations (i.e., seen in
more than one affected individual). The three hotspot PIK3CA mutations (p.Glu542Lys, p.Glu545Lys, and
p.His1047Arg) are highly recurrent (i.e., seen frequently) in pediatric disorders. We found that two “nonhotspot mutations” (p.Glu726Lys and p.Gly914Arg) are also highly recurrent in developmental phenotypes, having now been detected in more than 10 patients each.
Most of these mutations are proven or predicted to have a gain-of-function (GOF) mechanism, and
oncogenic mutations at all of these amino acid sites have been seen in COSMIC (13). Published functional studies demonstrate a GOF mechanism for at least 9 of 41 mutations. For another 8 mutations,
GOF has been shown for different missense mutations at the same codon (13). For example, our study
identified p.Asn345Thr, p.Glu545Asp, and p.Gln546His mutations, while GOF has been shown for
p.Asn345Lys, p.Glu545Lys, p.Glu545Gly, p.Gln546Lys, and p.Gln546Pro. We also detected p.Tyr1021His
and p.Ala1035Thr mutations in our series, while p.Tyr1021Cys and p.Ala1035Val mutations have been
found in other patients (16). Further, Glu545Ala and Glu545Lys mutations have been previously detected
in individuals with undefined “Cowden-like” features as well (30).

Clinical results
The clinical features of all mutation-positive individuals are listed in Supplemental Tables 2 and 3. Clinical
photographs and brain MRI images of some of these individuals are shown in Figures 3–5. Based on clinical and molecular characteristics, these patients can be segregated into three groups, as follows.
insight.jci.org   doi:10.1172/jci.insight.87623
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Figure 3. Clinical photographs of MCAP patients. (A) Facial photograph of patient LR14-323 (p.Arg83Gln). (B–D) Photograph of the face (B), occipital
region (C), and left foot (D) of LR13-359 (p.Pro104Leu) showing MEG, occipital capillary malformation, and syndactyly of the second, third, and fourth
toes. (E) Computed tomography (CT) image of LR01-060 (p.Pro104Leu) showing the subcutaneous hemangioma (arrowheads). (F) Photograph of
the trunk of LR12-080 (p.Arg115Pro) showing cutaneous capillary malformation with midline delineation. (G) Photograph of LR12-365 (p.Asn345Thr)
showing diffuse capillary malformations, MEG with a prominent forehead, and postaxial polydactyly of the left hand. (H) Photograph of LR13-036
(p.Glu365Lys) showing MEG, a disproportionately small body, and short extremities (clinically diagnosed with rhizomelic shortening of the extremities).
(I) Photograph of LR11-418 (p.Cys378Tyr) showing diffuse capillary malformations and apparent megalencephaly (MEG). (J and K) Photograph of the
face (J) and left foot (K) of LR12-330 (p.Glu545Asp) showing clear MEG, capillary malformation of the philtrum, skin laxity of the forehead, and syndactyly of the second, third, and fourth toes. (L and M) Photographs of the face (L) and body (M) of LR13-038 (p.Gly914Arg) showing MEG, reticulated
capillary malformations, pigmented nevus of the right arm, and asymmetry of the legs. (N and O) Photographs of the chest (N) and lower extremity
(O) of LR12-383 (p.Gly914Arg) showing clear asymmetry of the trunk involving the right breast and overgrowth of the right leg with prominent venous
network. (P and Q) photographs of the left (P) and right (Q) feet of LR11-081 (p.Thr1025Ala) showing bilateral asymmetric macrodactyly, sandal-gap
toes, and capillary malformations. (R) Photograph of the feet of LR13-169 (p.Ala1035Thr) showing syndactyly of the second, third, and fourth toes on
the right, and second and third toes on the left. (S and T) photographs of the face (S) and lower extremities (T) of LR12-328 (p.Met1043Ile) showing
facial and body asymmetry, MEG with a prominent forehead, and capillary malformations on the face and body.

Group 1: MCAP syndrome. Most individuals with mosaic PIK3CA mutations in our cohort (n = 50) had
classic features of MCAP, characterized by brain overgrowth (megalencephaly) and cutaneous vascular
malformations, with variable body overgrowth, connective tissue laxity, and digital anomalies (polydactyly
and syndactyly) (Figure 3) (31, 32). Several of our MCAP patients had additional noteworthy clinical findings including (a) complex structural heart defects or arrhythmias (n = 12), (b) lymphatic malformations
including chylothorax and lymphedema (n = 5), (c) predisposition to thrombosis (n = 3), (d) endocrine disorders including hypothyroidism (n = 3), growth hormone deficiency (n = 2), and rhizomelic shortening of
the extremities (n = 3). Six patients had episodes of hypoglycemia (Supplemental Tables 2 and 3). Interestingly, several of our MCAP patients (n = 6) had constitutional (or apparently constitutional) mutations in
PIK3CA (including LR14-323, LR14-278, LR14-358, LR13-048, LR15-227, and LR15-246). Two of these
patients (LR15-227 and LR15-246) had the p.Glu726Lys mutation.
Group 2: intermediate phenotypes — capillary malformations with overgrowth and lipomatosis (CMO, CMOL).
Several patients (n = 7) had novel phenotypes with features either overlapping MCAP but lacking megalencephaly or suggesting a milder variant of CLOVES. Patient LR15-238 had mild somatic hemihypertrophy
and cutaneous vascular malformations (facial capillary malformation, and reticulated diffuse capillary malformations on the body), but was normocephalic. She had perinatal bradycardia, transient dilated cardiomyopathy, and a history of possible nonocclusive venous thrombosis in the internal jugular vein of unknown
etiology. She had the p.Arg93Gln mutation in 19% of alleles in peripheral blood lymphocytes. Interestingly,
the same mutation was identified in another patient with classic features of MCAP (LR14-323). The mutation in the latter patient appeared to be constitutional, seen in ~50% of alleles in blood- and saliva-derived
DNA. Patient LR11-082 had congenital onset somatic overgrowth, diffuse congenital livedo reticularis and
syndactyly, as well as severe joint laxity and multiple joint dislocations (Figure 4, A–D). She was normocephalic, and brain MRIs performed at 5 days and 6 months of age showed no cortical malformation. Interestingly, she had progressive cerebellar tonsillar ectopia and a markedly large cerebellum on her MRI at 6
months (Figure 5, A and B). This patient harbored the p.Gly106Val mutation in 34% and 40% of alleles in
blood and skin, respectively. Patient LR12-131 had hemihypertrophy, capillary malformation on the philtrum and midline lower lip, a capillary malformation on the right arm, and toe syndactyly, but lacked other
classic features of MCAP. He had a mosaic p.Cys378Tyr mutation in 7% of alleles in blood-derived DNA.
Patient LR12-070 had congenital hemihypertrophy, epidermal nevi, and lipomatous overgrowth of the
trunk that was characteristically milder than CLOVES (Figure 4, E–G). He also had overlying capillary malformations, and macrodactyly requiring surgical excision. He harbored the p.Glu453Lys mutation in 25%
of alleles in fibroblasts. This mutation was undetectable in saliva. Patient LR12-184 had diffuse asymmetric
somatic overgrowth, reticulated port-wine stain, syndactyly, and connective tissue laxity. He was normocephalic, with no cortical malformations, and normal cognition. Interestingly, his brain MRI scan at age 2
months showed severe cerebellar tonsillar ectopia (Figure 5C). He subsequently developed sporadic swelling
of the neck believed to be due to lymphatic fluid accumulation. He harbored the p.Glu453Lys mutation at
variable levels (ranging from 5%–17% of alleles in affected skin regions, 24.5% in saliva, and 0.9% of alleles
in blood-derived DNA). Patient LR12-329 had hemihypertrophy, cutaneous vascular malformations, and
multiple cutaneous lipomas, but lacked classic features of MCAP or CLOVES. He had the p.Glu453Lys
mutation in 6% of alleles in saliva. Patient LR13-045 also had hemihypertrophy and diffuse congenital liveinsight.jci.org   doi:10.1172/jci.insight.87623
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Figure 4. Clinical photographs of PIK3CA
mutation–positive patients with segmental
overgrowth. (A–D) Photographs at 1 year (A),
birth (B), right foot (C), and left foot (D) of
LR11-082 (p.Gly106Val) showing diffuse and
asymmetric body overgrowth, diffuse capillary
malformations, bilateral syndactyly of second,
third, and fourth toes, and joint hypermobility.
(E–G) Photograph of the body (E and F) and
left foot (G) of LR12-070 (Glu453Lys) showing
asymmetric overgrowth, capillary malformations with midline delineation, and postsurgical changes after resection of the second toe
due to severe macrodactyly. (H and I) Facial
photographs of patient LR12-183 (p.Glu542Lys)
showing multiple epidermal nevi. (J and K) Photographs of LR12-172 (p.His1047Arg) showing
macrodactyly of the left hand.

do reticularis but lacked megalencephaly.
He had the p.Gly914Arg mutation in 5%
and 15% of alleles in normal and affected
skin-derived fibroblasts, respectively. This
mutation was undetectable in salivaderived DNA.
Group 3: hotspot-associated phenotypes
(CLOVES/DMEG). Four patients harbored
hotspot PIK3CA mutations most commonly seen in cancer. Two of these patients had
a mosaic p.Glu542Lys mutation. Patient
LR12-183 had a novel constellation of
features including megalencephaly with
diffuse cortical dysplasia, partial agenesis
of the corpus callosum, dysplasia/hypoplasia of the cerebellar vermis and hemispheres, diffuse dysmyelination, abnormal
high T2 signal intensities in the red nuclei
and thalami bilaterally, and a very large
tectum (Figure 5, D–G). He also had multiple linear sebaceous nevi on the face and
trunk (Figure 4, H and I). This combination of features meets criteria for linear
nevus sebaceous or Schimmelpenning
syndrome (33–35). This patient’s mutation was seen in 39/139 (28%) of alleles
in saliva-derived DNA. Patient LR13-197
had diffuse megalencephaly with bilateral
cortical dysplasia, hippocampal dysplasia,
white matter dysmyelination, and dysplastic ventricles bilaterally (Figure 5, H and
I). She harbored the p.Glu545Lys mutation at 26% of alleles in saliva-derived DNA. Patients LR13-172 and LR13-265 both had very low-level
mosaic p.His1047Arg mutations. Patient LR13-172 had megalencephaly with macrodactyly and harbored
the mutation in 1% of alleles in blood-derived DNA (Figure 4, J and K). Patient LR13-265 had features of
CLOVES syndrome with lipomatous overgrowth involving the face and trunk, prominent venous network
in the abdominal wall, verrucous overgrowth of the trunk, and macrodactyly. His mutation was present in
4% of affected skin-derived DNA, and absent from several unaffected skin samples. We also obtained addiinsight.jci.org   doi:10.1172/jci.insight.87623
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Figure 5. Brain MRI images of PIK3CA mutation–positive
patients. (A and B) LR11-082. T1-weighted mid-sagittal
(A) and T2-weighted axial (B) image at age 6 months
showing a large cerebellum, crowded posterior fossa with
cerebellar tonsillar ectopia, and a relatively normal cortical
gyral pattern (arrowhead). (C) LR12-184. T1-weighted midsagittal image showing marked cerebellar tonsillar ectopia
(arrowhead). (D–H) LR12-183. T1-weighted mid-sagittal (D),
T2-weighted axial (E and G), and coronal (F) images showing diffuse cortical dysplasia, partial agenesis of the corpus
callosum, dysplasia/hypoplasia of the cerebellar vermis
and hemispheres, diffuse dysmyelination, abnormal high
T2 signal intensities in the red nuclei and thalami bilaterally (red arrows in E and F), and a very large tectum (red
arrow in D). (H and I) LR13-197. T1-weighted mid-sagittal
(H) and T2-weighted axial (I) images showing bilateral
cortical dysplasia, hippocampal dysplasia, white matter
dysmyelination, and bilaterally dysplastic ventricles. There
is mild cerebellar tonsillar ectopia (arrow in H).

tional information on a previously reported patient
(LR12-033) (16, 36) who demonstrates features of
both dysplastic megalencephaly (effectively bilateral
hemimegalencephaly) and CLOVES syndrome, making her only the second reported child with this severe
combination. She had severe asymmetric overgrowth,
diffuse soft tissue swelling consistent with lymphedema, asymmetric head, severe hypotonia, and possible
right optic nerve hypoplasia (Supplemental Figure 5).
Constitutional PIK3CA mutations. Ten individuals in our cohort harbored constitutional (or apparently
constitutional) mutations of PIK3CA that were detectable in peripheral samples (blood or saliva) at AAPs
ranging from 35%–60% (LR14-323, LR01-060, LR15-076, LR13-036, LR14-278, LR14-358, LR13-048,
LR15-227, LR12-330, LR15-246, and LR12-340). Interestingly, seven of these individuals had features of
MCAP. However, three had diffuse brain or body overgrowth without segmental or patchy manifestations.
Patient LR15-076 had diffuse megalencephaly, a small patent foramen ovale, and pectus excavatum deformity. Patient LR13-036 had a unique constellation of features including megalencephaly with rhizomelic
shortening of the extremities, polydactyly, complex cardiac defects (left-sided aortic arch, ventricular septal
defect, atrial dilatation), recurrent hypoglycemia, omphalocele, organomegaly, laryngeal stenosis, and recurrent infections, partially overlapping with Beckwith-Wiedemann syndrome. Patient LR12-340 had somatic
asymmetry, was tall for age, with bilateral 2-3 toe syndactyly, but lacked megalencephaly and vascular anomalies. Mutations in five of these individuals were detected by clinical WES. These PIK3CA mutations were
detected in blood at standard coverage (20× to 30×), suggesting constitutional mutations. Of note, bloodderived DNA was not available for analysis on four of these individuals (LR12-340, LR01-060, LR11-200,
and LR12-330). Therefore, the possibility of mosaicism cannot be excluded in these patients.

Discussion
Classification of PIK3CA-associated developmental phenotypes. GOF mutations of PIK3CA have been associated
with a wide spectrum of pediatric phenotypes (Figure 6). The original and best known of these is KTS,
which was first defined more than a century ago based on the now classic triad of capillary malformation,
venous varicosities, and limb hypertrophy (37–39). However, published photographs of KTS vary considerably in appearance. Therefore, it appears that KTS is often used as an umbrella term for any disorder
with vascular malformation and overgrowth. Several recently described syndromes appear to be more specific designations, and we have predominantly used these in analyzing our phenotypic data. CLOVES is
the most severe KTS-like disorder. In practice, most patients with CLOVES have all of the anomalies in
the mnemonic (above), dramatic postnatal progression of the segmental overgrowth and lipomatosis, and
other abnormalities (19, 40, 41). A subset of patients with most but not all of the features of CLOVES has
been designated as fibroadipose overgrowth/hemihyperplasia-multiple lipomatosis, but the criteria used to
insight.jci.org   doi:10.1172/jci.insight.87623
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Figure 6. The PI3K-AKT-MTOR–related developmental brain disorders spectrum. Diagram showing the PI3K-AKT-MTOR pathway highlighting genes
associated with developmental brain disorders including PIK3CA, PIK3R2, PTEN, AKT3, MTOR, CCND2, DEPDC5, NPRL2, and NPRL3 (shown in blue), as well
as TSC1 and TSC2 genes (shown in red).

separate them are unclear (10, 21). Capillary malformation with overgrowth (CMO) is a recently defined
clinical entity characterized by extensive, diffuse, reticulate capillary malformations and variable hypertrophy without major complications (42). The phenotype is much less severe than CLOVES, although some
patients with apparent CMO in infancy go on to develop lipomatosis at older ages. Several other relatively
mild phenotypes that overlap with CMO have also been described, including the “girth” and “RCM” types
of vascular malformations with overgrowth (43). MCAP is characterized by symmetric or only mildly asymmetric brain overgrowth (megalencephaly) and cutaneous vascular malformations (predominantly capillary
malformations), with variable malformations of cortical development (polymicrogyria), body overgrowth,
digital anomalies (syndactyly and less often polydactyly), and connective tissue laxity (31, 32, 44, 45).
Beyond these multisystem disorders, mosaic mutations of PIK3CA have recently been identified in
localized or focal forms of overgrowth with dysplasia including epidermal nevi (17), isolated macrodactyly
(22), infiltrating lipomatosis (25, 46), isolated lymphatic malformations (28), and, most recently, venous
malformations (29). Further, several patients with focal brain involvement, including dysplastic megalencephaly (DMEG), hemimegalencephaly (HMEG), and focal cortical dysplasia (FCD) have been identified
as well (20, 27, 36). These disorders have been associated with variable but often low levels of mutations
in affected tissues, and very low or undetectable levels in apparently unaffected tissues, such as peripheral
blood lymphocytes. Finally, several patients have been reported with constitutional mutations of PIK3CA
associated with isolated megalencephaly or unspecified “Cowden-like” features (30, 47).
Several recent reviews have presented PIK3CA-associated phenotypes as essentially a single broad
spectrum (10). However, the original phenotype descriptions and the molecular data presented here argue
otherwise. We view the differences between the clinical presentation as consistent and recognizable, based
on our observations in the largest series of mosaic mutations of a single gene underlying developmental
disorders reported to date. We propose that the PIK3CA-associated spectrum of disorders should serve
as a paradigm for mosaic disorders. The clinical differences between MCAP and CLOVES (including
CLOVES-DMEG) syndromes are summarized in Table 5. In MCAP, head and brain overgrowth are often
the presenting signs, while body overgrowth at birth is mild (+1 to +2 SD) with stature normalizing by ~8
years (32). The cutaneous vascular malformation typically presents as congenital livedo reticularis (38).
The head and body overgrowth and livedo reticularis are most often diffuse with subtle asymmetry. About
60%–70% of patients have a cortical malformation, with imaging and clinical features consistent with bilatinsight.jci.org   doi:10.1172/jci.insight.87623
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Table 5. Comparison of intermediate and hotspot PIK3CA gain-of-function phenotypes
Feature/Group

Brain size
Malformations of cortical development
Skin capillary malformation
Skin pigmented nevus
Body overgrowth congenital
Body overgrowth postnatal
Lipomas-lipomatosis
Lymphatic malformation

Less-activating mutations (MCAP)

Hotspot mutations (CLOVES, DMEG)

Large
Normal or PMG
Congenital livedo reticularis
(none)
Diffuse, mild asymmetry
No
Few and small
Rare and small

Normal
DMEG-HMEG-FCD type 2
Port-wine stain
Epidermal nevi
Segmental and severe
Severe
Many large and grow
Frequent and large

Abbreviations: CLOVES, congenital lipomatous truncal overgrowth, vascular anomalies, epidermal nevi and skeletal/spinal anomalies; DMEG,
dysplastic megalencephaly; FCD, focal cortical dysplasia;HMEG, hemimegalencephaly; MCAP, megalencephaly-capillary malformation syndrome;
PMG, polymicrogyria.

eral perisylvian polymicrogyria (31, 32). Lipomas, lymphatic malformations, and macrodactyly occur, but
are typically uncommon, limited in size, do not progress, and rarely require surgical intervention. Epidermal nevi are rare. In CLOVES, on the other hand, head and brain size are typically normal, although rare
patients with combined CLOVES and DMEG have been observed (i.e., LR12-033). The cutaneous vascular malformations have a variable presentation from a classic port-wine stain appearance to pale pink or red
capillary malformations. Body overgrowth including macrodactyly, lipomas, and lymphatic malformations
are segmental and often severe with rapid postnatal progression. Epidermal nevi are common (19, 41).
Our data also show that the mutational spectrum of these disorders is different. The mutations associated with MCAP syndrome in particular are distinct from other PIK3CA-related overgrowth disorders. The
mutational spectrum in MCAP is broad, with greater than 20 milder GOF mutations seen across the entire
gene, whereas most mutations seen in CLOVES, KTS, DMEG, and other focal forms of overgrowth (such as
isolated macrodactyly) are more often associated with the cancer hotspot mutations. Given this wide mutational spectrum, we recommend using a broad molecular strategy that tests the entire PIK3CA coding sequence,
rather than targeted mutation screening of common mutations in individuals with similar phenotypes. Several
individuals lacked megalencephaly, and had variable somatic overgrowth with vascular malformations, further expanding the spectrum of PIK3CA-related overgrowth. Therefore, the molecular data on PIK3CA-related
overgrowth disorders to date show that they comprise a discontinuous spectrum of disorders that correlate well
with the severity (strength of GOF) and distribution of the mutation, rather than a single continuous spectrum.

Diagnosis of mosaicism in developmental disorders
Genetic disorders caused by postzygotic (or mosaic) variants are increasingly recognized with the advent of
deep NGS methods. The contribution of mosaic variation to developmental brain disorders has also been
increasingly appreciated in various segmental disorders including HMEG, FCD, and, more recently, bilateral
perisylvian polymicrogyria (16, 20, 27, 36, 48–51). However, detecting low-frequency mosaic variants in clinical practice remains challenging for several reasons. First, the availability of nonblood tissue sources (such as
affected skin or brain) may be limited. Second, available diagnostic testing methods used in clinical diagnostic
labs (such as Sanger sequencing or standard-depth NGS) are insufficiently sensitive to detect mosaic variation.
We therefore sought to address these issues by sequencing large cohorts of samples from individuals with
overgrowth in general, and MCAP in particular, using 2 independent deep-targeted NGS methods that utilize
MIPs and amplicon deep sequencing. These methods have been particularly demonstrated to be effective for
detecting low-frequency variants (14, 15). When combined with single-molecule tagging with multiplex targeted sequencing (smMIPs), the MIP method further increases the sensitivity for the detection of low-frequency
variants, as single-molecule tagging marks sequences derived from a common progenitor molecule. Our results
also challenge the current clinical practice of using blood-derived DNA for almost all clinical genetic testing.
Our study suggests that a change in clinical practice is indicated for disorders suspected to be associated with
somatic mosaicism, such as those involving asymmetry or other segmental or focal presentation, i.e., as a large
majority of vascular malformations, overgrowth, cutaneous pigmentary abnormalities, noncancerous dysplasia (i.e., epidermal nevi).
insight.jci.org   doi:10.1172/jci.insight.87623
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Summary
Our data expand on the molecular and phenotypic spectrum of PIK3CA-related developmental disorders.
First, we show that the mutational spectrum in children with MCAP is broader than other PIK3CA-related
overgrowth disorders. Further, we report on several atypical or expanded phenotypes, including children
with body overgrowth without megalencephaly, that appear milder than CLOVES and other severe forms
of somatic overgrowth. Finally, we report on constitutional mutations of PIK3CA in a subset of children,
some of whom have milder features such as diffuse megalencephaly with intellectual disability, similar to
the PTEN-related disorders (52). Based on our data and review of the literature, we propose a molecularly
based classification of these disorders. Overall, our molecular studies in this large series show that phenotypes of mosaic disorders are impacted not only by tissue distribution and levels of mosaicism, but also
by class (strength of activation) of mutation. Our series helps inform best clinical practices for diagnostic
methods and tissues to sample in mosaic disorders broadly.

Methods
Sample processing. Genomic DNA was extracted from blood using the Puregene Blood Core Kit (QIAGEN), saliva using the Oragene Saliva Kit (DNA Genotek), buccal cells from Oragene Saliva Kits following centrifugation, and skin fibroblasts following a skin biopsy. Fibroblasts were grown in DMEM/F12
with glutamine, supplemented with 10% FBS and 1% PenStrep (all three from Gibco). DNA was extracted
both directly and from fibroblasts after digesting with proteinase K in Cell Lysis Buffer (both QIAGEN)
using prepIT.L2P (DNA Genotek) and ethanol precipitation. Lymphocytes were separated from whole
blood using Ficoll and subsequently transformed to lymphoblastoid (LB) cell lines using Epstein-Barr virus
(EBV) in RPMI 1640 media with glutamine, supplemented with 10% FBS and 1% PenStrep (all three from
Gibco). Genomic DNA was then extracted using a Puregene Blood Core Kit.
Multiplex targeted sequencing using smMIPs. We designed a pool of 48 smMIP oligonucleotide probes
targeting the coding sequences of PIK3CA. smMIPs tiled across a total of 3,340 bp of genomic sequence,
including 100% of the 2,202 coding bp of PIK3CA. One hundred–nanogram capture reactions were
performed in parallel. Massively parallel sequencing was performed with the Illumina HiSeq. Variant
analysis was performed using our previously published pipeline including MIPgen and PEAR version
0.8.1 (48, 53). All missense, nonsense, and splice site variants seen at a frequency of less than 1% in
public databases, in 2 or more capture events were retained for analysis. Our MIP capture method has
been previously published (48).
Amplicon sequencing. Amplicon sequencing was performed using previously published methods (48).
We performed locus-specific amplification of genomic DNA followed by GS Junior sequencing (Roche).
We designed fusion primers containing genome-specific sequences along with distinct multiplex identifier
sequences (used to differentiate samples being run together on the same plate) and sequencing adapters,
to generate amplicons ranging in size from 290 to 310 bp, using Primer3Plus software. Primer sequences
are provided in Supplemental Table 4. Small DNA fragments were removed with Agencourt AMPure
XP (Beckman Coulter) according to the manufacturer’s protocol. All amplicons were quantified with
the Quant-iT PicoGreen dsDNA reagent (Life Technologies), pooled at equimolar ratios, amplified by
emulsion PCR using the GS Junior Titanium emPCR kit (Lib-A kit, Roche Applied Science), and pyrosequenced in the sense and antisense strands on a GS Junior sequencer following the manufacturers’ instructions. Data were analyzed using GS Amplicon Variant Analyzer version 3.0 software.
WES. WES produced 18.2 GB of sequencing data per proband. Mean coverage of captured regions
was ~250× for proband samples, with ~99.17% covered with at least 10× coverage, an average of 89.82%
of base call quality of Q30 or greater, and an overall average mean quality score of Q35. WES was performed using previously published methods (54).
Targeted NGS. This assay sequenced all exons of PIK3CA, and average coverage ranged from 320 to
greater than 1,000 sequencing reads per bp. Genomic regions were captured using biotinylated RNA oligonucleotides (SureSelect), prepared in paired-end libraries with ~200-bp insert size, and sequenced on an
Illumina HiSeq2500 instrument with 100-bp read lengths, in a modification of a previously reported pipeline
(55). Large deletions and duplications were detected by this panel using previously published methods (56).
Statistics. We completed a pairwise comparison of mean values for alternative allele percentages in the three
tissue types, where a 2-tailed t test gave P values of 0.0352, 0.0365, and 0.566 for blood versus saliva, blood
versus skin, and saliva versus skin, respectively. A P value less than 0.05 was considered statistically significant.
insight.jci.org   doi:10.1172/jci.insight.87623
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Study approval. This study was approved by the IRB at Seattle Children’s Hospital. Informed consent
was obtained from subjects prior to enrollment in the study, except for subjects whose samples and clinical
data were sent without identifying information. De-identified subjects were included under IRB waiver of
consent, per IRB protocol at Seattle Children’s Hospital. Written informed consent was provided for use of
the patients’ photographs in the clinical figures of this manuscript.
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